Catalent (CTLT)
(Delayed Data from NYSE)
$58.40 USD
-0.02 (-0.03%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $58.42 +0.02 (0.03%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 201 - 217 ( 217 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Research Summary
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Acquisition Increases Biologics Exposure at a Reasonable Price
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Research Summary
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Morning Call
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Downgrade to SW Big Shift in Investor Sentiment Y/Y Reflected in Valuation.
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
While Not Imminent, Taking into Account Industry M-A in Its Valuation
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
While Not Imminent, Taking into Account Industry M-A in Its Valuation.
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Raise PT to $35; Biologics May Emerge as an Investable Theme Moving Forward
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Even When Results Are Good, Focus on the Year, Not the Quarter
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Biopharma Services: PTHN and CTLT Could Take an Extended Look If AMRI Is Looking to Sell
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Raise Price Target to $31; Solid Execution Increases Confidence in Back Half Weighted Guidance
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Medical Technology: 4Q Preview; No Real Changes to Outlooks; Reducing Estimates Again for FX
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Life Sciences Tools - Services,CDMO Consolidation Trend Ongoing.
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Good Example of the LT Opportunity to Consolidate Fragmented Landscape
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
1Q Execution Another Modest Step Toward Improved Investor Sentiment
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Morning Meeting Notes
Provider: KEYBANC CAPITAL MARKETS
Company: Catalent, Inc.
Industry: Medical - Drugs
Expecting Investor Sentiment to Improve Through FY17; Initiate OW - $29 PT
Provider: KEYBANC CAPITAL MARKETS